Clinical trial
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
NCT06466525 is registered in ClinicalTrials.gov with Longevity Biotech Australia Pty Ltd (subsidiary) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
- Lead sponsor
- Longevity Biotech Australia Pty Ltd (subsidiary)
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 16, 2024
- Completion date
- February 28, 2027
- Enrollment
- 64 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.